# MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

> **NCT03799913** · EARLY_PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** anti-MESO CAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03799913
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-10
- **Primary completion:** 2021-10
- **Final completion:** 2022-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-04-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799913, "MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT03799913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*